DAA Therapy in Pediatric Patients With Chronic Hepatitis C
Direct Acting Antiviral Agent (DAA) Therapy Is Safe and Efficacious in Pediatric Patients With Chronic Hepatitis C: Real World Data From the Public Health Perspective
Sponsor: Directorate of Health and Family Welfare, Punjab
A NA clinical study on Chronic Hepatitis c, this trial is ongoing. The trial is conducted by Directorate of Health and Family Welfare, Punjab and has accumulated 8 data snapshots since 2016. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
8 versions recorded-
Jul 2025 — Present [monthly]
Unknown NA
-
Sep 2024 — Jul 2025 [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Apr 2024 — Jul 2024 [monthly]
Unknown Status NA
-
Oct 2021 — Apr 2024 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Recruiting NA
-
Jul 2019 — Jan 2021 [monthly]
Recruiting NA
-
Apr 2018 — Jul 2019 [monthly]
Recruiting NA
First recorded
Jun 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Directorate of Health and Family Welfare, Punjab
- Post Graduate Institute of Medical Education and Research, Chandigarh
For direct contact, visit the study record on ClinicalTrials.gov .